Mechanistic Plausibility of Unified Bioactive Compound Supplementation in Modulating Inflammation and Cardiovascular Risk: A Hypothesis-Driven Analysis

Walter Pereira

https://doi.org/10.1590/SciELOPreprints.16015

Submitted on: 2026-05-01
Posted on: 2026-05-12 (version 1)
(YYYY-MM-DD)

Mechanistic Plausibility of Unified Bioactive Compound Supplementation in Modulating Inflammation and Cardiovascular Risk: A Hypothesis-Driven Analysis

Walter Pereira Pinto[1 2 3 4]

Orcid: **https://orcid.org/0000-0002-9954-8441**

Correspondência: waltersparta@performancehealthscience.com

Institutional Affiliations:

1 Time Ciência e Performance, Brazi.

2 Performance and Health Science USA corporation

3 Instituto UNA Brazil – Coordenadoria de assuntos científicos

4 Inovattis Health Science, Brazil

Keywords: Dietary supplements, Polyphenolic compounds, Oxidative stress, Inflammation, Cardiovascular health, Mechanistic hypothesis

ABSTRACT

Background: Chronic low-grade inflammation and oxidative stress are implicated in the pathogenesis of cardiovascular disease and metabolic syndrome. Bioactive compounds derived from botanical sources possess antioxidant and anti-inflammatory properties that may theoretically modulate these pathophysiological processes. However, the mechanistic plausibility of unified supplementation strategies combining multiple bioactive agents remains underexplored.

Objective: To present a hypothesis-driven, mechanistic analysis of the potential synergistic effects of a unified bioactive compound formulation—comprising flavonoids, *Chlorella vulgaris*, green tea catechins, *Citrus sinensis* anthocyanins, spirulina, psyllium fiber, and fenugreek—on inflammatory pathways, oxidative stress, and cardiovascular risk biomarkers.

Methods: This theoretical analysis synthesizes existing evidence from preclinical and clinical studies examining individual bioactive compounds. The proposed mechanistic framework integrates known molecular pathways through which these compounds may influence redox homeostasis, cytokine production, lipid metabolism, and endothelial function.

Key Mechanistic Insights: Individual bioactive compounds demonstrate capacity to modulate nuclear factor-κB (NF-κB) signaling, reduce pro-inflammatory cytokine expression (interleukin-6, tumor necrosis factor-α), enhance endogenous antioxidant enzyme activity, improve lipid profiles, and attenuate insulin resistance through multiple molecular pathways. The hypothesis of synergistic or additive effects from unified supplementation is supported by complementary mechanisms of action, including free radical scavenging, immunomodulation, and upregulation of antioxidant response elements. However, direct experimental validation of combined formulations is lacking.

Conclusion: The mechanistic rationale for unified bioactive compound supplementation in cardiovascular health is theoretically plausible based on individual compound evidence and complementary pathways. This hypothesis-driven framework provides a foundation for future controlled experimental studies to evaluate safety, bioavailability, potential interactions, and clinical efficacy of combined formulations. Translational application requires rigorous investigation through appropriately designed clinical trials.

TABLE OF CONTENTS

1. Introduction
2. Pathophysiological Background
   - 2.1 Oxidative Stress and Cardiovascular Pathophysiology
   - 2.2 Chronic Inflammation and Metabolic Syndrome
3. Bioactive Compounds and Nutritional Components
   - 3.1 Flavonoids
   - 3.2 *Chlorella vulgaris*
   - 3.3 Green Tea (*Camellia sinensis*)
   - 3.4 *Citrus sinensis* (Moro Orange)
   - 3.5 Spirulina
   - 3.6 Psyllium (*Plantago ovata*)
   - 3.7 Fenugreek (*Trigonella foenum-graecum*)
4. Mechanisms of Action
   - 4.1 Antioxidant Pathways
   - 4.2 Anti-inflammatory Signaling
   - 4.3 Lipid Metabolism and Adipocytokine Regulation
   - 4.4 Insulin Sensitivity and Glucose Homeostasis
5. Integrated Physiological Model
6. Translational Implications
7. Limitations
8. Conclusion
9. Conflict of Interest
10. Data Availability Statement
11. References

1. INTRODUCTION

Dietary supplements are defined as food components, nutrients, or bioactive compounds intentionally consumed beyond habitual dietary intake to achieve specific health or performance outcomes, as delineated in the International Olympic Committee consensus statement [1]. The United States Dietary Supplement Health and Education Act (DSHEA) of 1994 characterizes dietary supplements as products—excluding tobacco—intended to supplement the diet and containing vitamins, minerals, herbs, botanicals, amino acids, or their derivatives [2]. Over the past three decades, utilization of natural remedies for health optimization and disease management has increased substantially [3], [4].

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, necessitating exploration of novel preventive and therapeutic strategies with favorable efficacy-to-safety profiles [5]. Accumulating evidence suggests that antioxidant compounds may play a protective role against oxidative stress-mediated pathology, including cardiovascular disorders, diabetes mellitus, and malignancies [6]. Oxidative stress, defined by the National Institutes of Health as an imbalance between reactive oxygen species (ROS) production and antioxidant defense capacity [7], contributes to endothelial dysfunction, accelerated vascular aging, and increased cardiovascular event risk [8], [9].

Contemporary epidemiological trends indicate rising prevalence of sedentary behavior and hypercaloric dietary patterns, contributing to metabolic syndrome (MetS)—a constellation of risk factors including abdominal obesity, insulin resistance, dyslipidemia, and hypertension [10]. Chronic low-grade inflammation, particularly adipose tissue-derived inflammatory mediators such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), is hypothesized to link metabolic dysregulation with cardiovascular risk [11], [12], [13].

Therapeutic strategies targeting inflammatory cell activity and cytokine production may theoretically attenuate chronic inflammatory pathology [14]. Current research efforts focus on identifying bioactive compounds capable of modulating oxidative and inflammatory pathways through nutritional, pharmacological, and biochemical mechanisms [15]. Despite growing interest, the scientific literature examining safety, bioavailability, and efficacy of combined bioactive compound formulations remains limited. This knowledge gap justifies a hypothesis-driven mechanistic analysis of potential synergistic effects of unified

supplementation on cardiovascular, metabolic, and inflammatory biomarkers—and their theoretical utility as adjunctive therapeutic approaches for chronic disease management.

---

2. PATHOPHYSIOLOGICAL BACKGROUND

2.1 Oxidative Stress and Cardiovascular Pathophysiology

Oxidative stress arises when ROS generation exceeds endogenous antioxidant capacity, resulting in oxidative damage to lipids, proteins, and nucleic acids [7]. In the cardiovascular system, oxidative stress promotes endothelial dysfunction through multiple mechanisms, including reduced nitric oxide (NO) bioavailability, increased expression of adhesion molecules, and activation of pro-inflammatory transcription factors [8]. Endothelial dysfunction is recognized as an early predictor of atherosclerotic disease and future cardiovascular events [9].

ROS, including superoxide anion (O_2^-), hydrogen peroxide (H_2O_2), and hydroxyl radical (•OH), are generated through mitochondrial respiration, NADPH oxidase activity, and enzymatic reactions. While physiological ROS levels serve essential signaling functions, excessive ROS production overwhelms antioxidant defenses—comprising superoxide dismutase (SOD), catalase, glutathione peroxidase, and non-enzymatic antioxidants—leading to cellular injury and vascular pathology.

2.2 Chronic Inflammation and Metabolic Syndrome

Inflammation represents a fundamental host defense mechanism; however, persistent low-grade inflammation contributes to tissue damage and chronic disease progression [11], [12]. Adipose tissue, particularly visceral adipose depots in overweight and obese individuals, undergoes phenotypic transformation characterized by macrophage infiltration and increased secretion of pro-inflammatory adipocytokines, including IL-6, TNF-α, and monocyte chemoattractant protein-1 (MCP-1) [13].

These inflammatory mediators are implicated in the pathogenesis of insulin resistance, endothelial dysfunction, and hypertension—core components of metabolic syndrome [10]. The proposed mechanistic framework (Figure 1, original manuscript) illustrates the

interconnected pathways linking adipose tissue inflammation, oxidative stress, insulin resistance, and cardiovascular risk. Elevated circulating IL-6 and TNF-α levels are associated with impaired insulin signaling through activation of c-Jun N-terminal kinase (JNK) and inhibitor of κB kinase (IKK) pathways, resulting in serine phosphorylation of insulin receptor substrate-1 (IRS-1) and subsequent insulin resistance [13].

Furthermore, chronic inflammation promotes dyslipidemia through increased hepatic very-low-density lipoprotein (VLDL) synthesis and reduced lipoprotein lipase activity, contributing to atherogenic lipid profiles. The interplay between oxidative stress and inflammation creates a self-perpetuating cycle that accelerates cardiovascular disease progression.

---

3. BIOACTIVE COMPOUNDS AND NUTRITIONAL COMPONENTS

3.1 Flavonoids

Flavonoids constitute a diverse class of polyphenolic secondary metabolites ubiquitously distributed in plant-based foods [16]. Epidemiological evidence suggests that dietary flavonoid intake is inversely associated with cardiovascular disease risk, potentially attributable to antioxidant, anti-inflammatory, and vasoprotective properties [17], [18]. The antioxidant capacity of flavonoids derives from their ability to donate hydrogen atoms or electrons to neutralize free radicals, chelate transition metals, and upregulate endogenous antioxidant enzyme expression [19].

Three principal mechanisms through which dietary antioxidants may modulate oxidative stress have been proposed: direct free radical scavenging (quantified by oxygen radical absorbance capacity, ORAC), immunomodulation, and activation of antioxidant response elements (ARE) that regulate transcription of antioxidant enzymes [20], [21], [22]. Flavonoid supplementation has been hypothesized to confer benefits for both athletic performance and chronic disease prevention, although clinical evidence remains heterogeneous [19].

3.2 *Chlorella vulgaris*

Chlorella vulgaris (Chlorophyta; Chlorellaceae) is a unicellular green microalga characterized by exceptional nutritional density, including polyunsaturated fatty acids, phenolic compounds, proteins, peptides, vitamins, and minerals [24]. Preclinical studies have demonstrated antioxidant, anti-inflammatory, and antiapoptotic properties of *C. vulgaris* extracts, with protective effects documented against nephrotoxic agents such as mercuric chloride, cadmium, and gentamicin [25], [26], [27], [28], [29].

Panahi et al. (2012) [30] conducted a clinical investigation evaluating *C. vulgaris* supplementation as adjunctive therapy in patients with non-alcoholic fatty liver disease (NAFLD). The study reported that addition of *C. vulgaris* extract to standard pharmacotherapy (metformin and vitamin E) was associated with favorable effects on serum transaminase levels, triglyceride concentrations, and insulin sensitivity indices, suggesting potential hepatoprotective utility [30].

The anti-inflammatory activity of *C. vulgaris* has been demonstrated in multiple experimental models. Chaudhari et al. [31] evaluated *C. vulgaris* extract in acute and chronic inflammatory paradigms, observing reduced expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in treatment groups compared to controls [31]. These effects are hypothesized to result from inhibition of nuclear factor-κB (NF-κB) signaling and modulation of cyclooxygenase-2 (COX-2) activity [32], [33].

3.3 Green Tea (*Camellia sinensis*)

Habitual consumption of green tea (*Camellia sinensis*) has been associated with favorable anthropometric and metabolic outcomes in observational studies. A cross-sectional investigation involving 1,210 adults reported that individuals consuming tea regularly for periods exceeding 10 years exhibited 19.6% lower body fat percentage and 2.1% reduced waist-to-hip ratio compared to non-consumers [34]. Prospective cohort data from the Netherlands suggested that higher dietary catechin intake was associated with attenuated body mass index (BMI) increase in women followed over 14 years [35].

Meta-analyses examining the effects of green tea catechins and caffeine on weight management have demonstrated modest but statistically significant reductions in body

weight and fat mass [36], [37], [38]. The primary bioactive constituents of green tea—epigallocatechin gallate (EGCG), epicatechin gallate (ECG), epigallocatechin (EGC), and epicatechin (EC)—are hypothesized to modulate energy expenditure, fat oxidation, and adipogenesis through multiple mechanisms, including activation of AMP-activated protein kinase (AMPK), inhibition of catechol-O-methyltransferase (COMT), and modulation of adipocyte differentiation pathways [39].

Narrative reviews suggest that green tea polyphenols may exert protective effects against diverse pathological conditions, including malignancies, obesity, diabetes mellitus, cardiovascular diseases, and neurodegenerative disorders, although clinical evidence varies in quality and consistency [39].

3.4 *Citrus sinensis* (Moro Orange)

Citrus sinensis (L.) Osbeck, particularly the Moro variety cultivated in the volcanic soils surrounding Mount Etna, Italy, is characterized by high anthocyanin content, conferring distinctive pigmentation and bioactive properties [40]. Moro orange extracts have demonstrated antioxidant, anti-inflammatory, antidiabetic, anti-obesity, antitumoral, neuroprotective, immunomodulatory, and cardioprotective activities in preclinical models [41].

The anti-adipogenic and metabolic effects of *C. sinensis* are attributed primarily to flavonoid content, particularly anthocyanins such as cyanidin-3-glucoside and cyanidin-3-(6″-malonyl-glucoside) [44]. In vitro and in vivo studies suggest that citrus flavonoids may modulate lipid metabolism through multiple mechanisms, including induction of lipolysis, inhibition of adipogenesis, reduction of intracellular lipid accumulation, and regulation of obesity-related enzymes [44], [45], [46].

Current evidence suggests that anthocyanins may regulate adipocytokine gene expression, including upregulation of adiponectin and modulation of leptin signaling, thereby improving insulin sensitivity and attenuating inflammatory responses [47]. Proposed molecular mechanisms include negative regulation of plasminogen activator inhibitor-1 (PAI-1) and IL-6 expression, both implicated in type 2 diabetes mellitus and obesity pathogenesis [47].

Additionally, anthocyanins may reduce intracellular ROS accumulation and attenuate insulin resistance through inhibition of JNK pathway activation [48].

3.5 Spirulina

Spirulina, initially classified within the plant kingdom based on photosynthetic capacity, is now recognized as a cyanobacterium based on genetic and biochemical characterization [49]. Spirulina species, particularly *Arthrospira platensis* and *Arthrospira maxima*, are rich in bioactive compounds, including β-carotene, phycocyanin, tocopherols, polyunsaturated fatty acids (notably γ-linolenic acid), phenolic compounds, and essential micronutrients. The nutritional value of spirulina was formally recognized by the Intergovernmental Institution for the Use of Microalgae Spirulina Against Malnutrition in the 1970s [50].

Beyond lipid-lowering and weight management effects, spirulina has demonstrated antiviral, anticancer, antioxidant, antidiabetic, anti-inflammatory, hepatoprotective, cardioprotective, and immunomodulatory properties in experimental studies [51], [52]. Calella et al. (2022) [53] conducted a systematic review examining spirulina supplementation effects on oxidative stress, immune function, inflammation, and physical performance in athletic and non-athletic populations. While some evidence supporting beneficial effects was identified, the authors concluded that robust clinical evidence remains insufficient in healthy populations; supplementation may be considered in athletes with suboptimal dietary antioxidant intake [53].

The antioxidant activity of spirulina is attributed to phycocyanin, a phycobiliprotein with demonstrated free radical scavenging capacity and ability to inhibit lipid peroxidation. Anti-inflammatory effects are hypothesized to occur through inhibition of COX-2 expression and suppression of NF-κB activation.

3.6 Psyllium (*Plantago ovata*)

Epidemiological evidence suggests an inverse association between dietary fiber intake and body weight [57]. Psyllium, derived from the seed husks of *Plantago ovata*, is a soluble fiber with established cholesterol-lowering properties. Dyslipidemia, characterized by elevated total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) with

reduced high-density lipoprotein cholesterol (HDL-C), represents a primary risk factor for cardiovascular disease and stroke, accounting for substantial global mortality [58].

Although statin therapy remains the cornerstone of lipid management, concerns regarding adverse effects and contraindications have motivated investigation of alternative or adjunctive approaches [59]. Multiple randomized controlled trials and meta-analyses have evaluated psyllium supplementation effects on lipid profiles [60], consistently demonstrating LDL-C reductions ranging from 6% to 24% and total cholesterol reductions of 2% to 20% compared to placebo [61]. Cholesterol-lowering efficacy appears more pronounced in studies with unrestricted diets and in individuals with elevated baseline cholesterol concentrations [61].

The mechanism of action involves formation of a viscous gel in the small intestine, which increases chyme viscosity, delays nutrient digestion and absorption, and enhances bile acid excretion, thereby upregulating hepatic LDL receptor expression and reducing circulating LDL-C [62]. Additional metabolic benefits have been observed in patients with metabolic syndrome and type 2 diabetes mellitus. Randomized trials suggest that psyllium supplementation may facilitate modest weight loss in overweight and obese individuals, potentially through enhanced satiety and reduced energy intake [63].

3.7 Fenugreek (*Trigonella foenum-graecum*)

Fenugreek (*Trigonella foenum-graecum* L., Fabaceae) is a leguminous plant with seeds containing approximately 175 identified bioactive compounds [65]. Major constituents include steroidal saponins (notably protodioscin), soluble fiber, phenolic acids, flavonoids, alkaloids (trigonelline, 4-hydroxyisoleucine), terpenes, fatty acid glycosides, and amino acid derivatives [66].

Systematic reviews and meta-analyses have demonstrated that fenugreek supplementation may favorably modulate glycemic and lipid profiles in individuals with diabetes mellitus and metabolic syndrome [66], [67]. Proposed mechanisms include delayed gastric emptying and carbohydrate absorption due to fiber content, enhanced insulin secretion through amino acid-mediated pathways (particularly 4-hydroxyisoleucine), improved peripheral insulin sensitivity, and inhibition of hepatic glucose production [66].

Fenugreek extracts have also demonstrated antioxidant [68], anti-inflammatory [69], immunomodulatory [70], and anti-lipogenic properties [71] in experimental models. The antioxidant activity is attributed to phenolic compounds and flavonoids, which scavenge free radicals and upregulate endogenous antioxidant enzyme expression. Anti-inflammatory effects are hypothesized to occur through inhibition of pro-inflammatory cytokine production and modulation of arachidonic acid metabolism.

---

4. MECHANISMS OF ACTION

4.1 Antioxidant Pathways

The bioactive compounds reviewed demonstrate multiple complementary antioxidant mechanisms. Direct free radical scavenging occurs through electron or hydrogen atom donation to neutralize ROS and reactive nitrogen species (RNS), thereby terminating oxidative chain reactions. Polyphenolic compounds, including flavonoids, catechins, and anthocyanins, possess hydroxyl groups that facilitate this electron transfer.

Indirect antioxidant effects involve upregulation of endogenous antioxidant defense systems through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Upon oxidative stress, Nrf2 dissociates from its cytoplasmic inhibitor Keap1, translocates to the nucleus, and binds to antioxidant response elements (ARE), thereby inducing transcription of antioxidant enzymes including SOD, catalase, glutathione peroxidase, glutathione reductase, and heme oxygenase-1 (HO-1). Several bioactive compounds, including EGCG and phycocyanin, have been shown to activate Nrf2 signaling in experimental models.

Metal chelation represents an additional antioxidant mechanism, as transition metals (iron, copper) catalyze Fenton reactions that generate highly reactive hydroxyl radicals. Polyphenolic compounds can chelate these metals, thereby preventing ROS generation.

4.2 Anti-inflammatory Signaling

Chronic inflammation is mediated primarily through NF-κB signaling, a central transcription factor regulating expression of pro-inflammatory cytokines, chemokines, adhesion molecules, and inducible enzymes (COX-2, inducible nitric oxide synthase). Multiple

bioactive compounds reviewed demonstrate capacity to inhibit NF-κB activation through diverse mechanisms, including prevention of IκB degradation, inhibition of IKK activity, and direct interference with NF-κB DNA binding.

Suppression of pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) has been documented for *C. vulgaris*, spirulina, green tea catechins, and anthocyanins in preclinical models. These effects may occur through inhibition of mitogen-activated protein kinase (MAPK) pathways, including extracellular signal-regulated kinase (ERK), p38 MAPK, and JNK, which regulate cytokine gene transcription.

Modulation of arachidonic acid metabolism through COX-2 and lipoxygenase inhibition represents an additional anti-inflammatory mechanism. Several polyphenolic compounds demonstrate COX-2 inhibitory activity, thereby reducing prostaglandin E_2 (PGE_2) synthesis and associated inflammatory responses.

4.3 Lipid Metabolism and Adipocytokine Regulation

The reviewed bioactive compounds may influence lipid metabolism through multiple pathways. Inhibition of pancreatic lipase and reduction of dietary fat absorption has been demonstrated for green tea catechins and psyllium fiber. Enhanced fatty acid oxidation through AMPK activation and peroxisome proliferator-activated receptor (PPAR) modulation may increase energy expenditure and reduce adipose tissue accumulation.

Regulation of adipocyte differentiation and lipogenesis occurs through modulation of key transcription factors, including PPARγ, CCAAT/enhancer-binding proteins (C/EBPs), and sterol regulatory element-binding protein-1c (SREBP-1c). Anthocyanins and catechins have been shown to inhibit adipogenesis and reduce intracellular lipid accumulation in vitro.

Adipocytokine regulation represents a critical mechanism linking metabolic and inflammatory pathways. Upregulation of adiponectin, an insulin-sensitizing and anti-inflammatory adipokine, has been observed with anthocyanin and catechin supplementation. Conversely, reduction of leptin, resistin, and pro-inflammatory adipokines may improve insulin sensitivity and attenuate systemic inflammation.

4.4 Insulin Sensitivity and Glucose Homeostasis

Improvement of insulin sensitivity through multiple mechanisms has been proposed for the reviewed compounds. Attenuation of oxidative stress and inflammation may restore insulin signaling by preventing serine phosphorylation of IRS-1 and preserving tyrosine kinase activity of the insulin receptor. Inhibition of JNK and IKK pathways, which mediate insulin resistance in response to inflammatory stimuli, represents a key mechanism.

Enhanced glucose uptake through increased glucose transporter 4 (GLUT4) translocation to the plasma membrane has been demonstrated for several compounds. AMPK activation, which promotes GLUT4 translocation independently of insulin signaling, may contribute to improved glucose homeostasis.

Delayed carbohydrate digestion and absorption through inhibition of α-amylase and α-glucosidase activity has been documented for fenugreek and psyllium, resulting in attenuated postprandial glycemic excursions. Additionally, soluble fiber increases chyme viscosity, further delaying nutrient absorption.

---

5. INTEGRATED PHYSIOLOGICAL MODEL

The mechanistic evidence reviewed supports a theoretical integrated model in which unified supplementation with complementary bioactive compounds may exert synergistic or additive effects on interconnected pathophysiological pathways (Figure 1, conceptual framework).

Oxidative Stress Attenuation: The combination of direct free radical scavengers (flavonoids, catechins, anthocyanins, phycocyanin, β-carotene) with compounds that upregulate endogenous antioxidant defenses (Nrf2 activators) may provide comprehensive redox homeostasis restoration. This multi-level antioxidant defense could theoretically exceed the capacity of individual compounds.

Inflammatory Cascade Modulation: Simultaneous targeting of multiple inflammatory pathways—including NF-κB inhibition, MAPK suppression, COX-2 downregulation, and pro-inflammatory cytokine reduction—through complementary mechanisms may achieve more robust anti-inflammatory effects than single-agent approaches. The combination of

immunomodulatory compounds (*C. vulgaris*, spirulina, fenugreek) with polyphenolic anti-inflammatory agents may provide synergistic suppression of chronic low-grade inflammation.

Metabolic Optimization: Integration of compounds targeting distinct aspects of metabolic dysfunction—including lipid absorption inhibition (psyllium), enhanced fatty acid oxidation (catechins), adipogenesis suppression (anthocyanins), and insulin sensitization (fenugreek, anthocyanins)—may theoretically address multiple metabolic syndrome components simultaneously. The combination of fiber-mediated delayed nutrient absorption with compounds enhancing insulin signaling and glucose uptake could provide comprehensive glycemic control.

Cardiovascular Protection: The proposed unified formulation addresses multiple cardiovascular risk factors, including dyslipidemia (psyllium, catechins, spirulina), endothelial dysfunction (antioxidants, NO bioavailability enhancement), arterial stiffness (anti-inflammatory agents), and thrombotic risk (PAI-1 downregulation by anthocyanins). This multi-target approach aligns with the multifactorial etiology of cardiovascular disease.

Adipocytokine Balance: Coordinated upregulation of beneficial adipokines (adiponectin) and suppression of pro-inflammatory adipokines (leptin, resistin, IL-6, TNF-α) through multiple compounds may restore adipose tissue homeostasis and improve systemic metabolic-inflammatory status.

The theoretical plausibility of synergistic effects is supported by the complementary and non-overlapping mechanisms of action, targeting distinct molecular pathways that converge on common pathophysiological outcomes. However, it must be emphasized that this integrated model remains hypothetical and requires rigorous experimental validation.

6. TRANSLATIONAL IMPLICATIONS

The mechanistic framework presented provides a theoretical foundation for translational research examining unified bioactive compound supplementation. Several considerations are relevant for potential clinical application:

Target Populations: The proposed formulation may theoretically benefit individuals with metabolic syndrome, pre-diabetes, dyslipidemia, overweight/obesity, or elevated cardiovascular risk who do not meet dietary antioxidant and fiber intake recommendations. Potential utility as adjunctive therapy to standard pharmacological interventions warrants investigation, although safety and drug-nutrient interactions must be carefully evaluated.

Dosage Optimization: Determination of optimal dosages for individual components within a unified formulation requires systematic investigation. Dosages should be based on established safe intake levels and bioavailability considerations. Potential interactions between components that may enhance or inhibit absorption and metabolism must be characterized.

Bioavailability and Formulation: Polyphenolic compounds exhibit variable and often limited bioavailability due to extensive first-pass metabolism, rapid conjugation, and limited absorption. Formulation strategies to enhance bioavailability—including microencapsulation, nanoparticle delivery systems, or co-administration with absorption enhancers—may be necessary to achieve therapeutic tissue concentrations.

Safety Profile: While individual components have generally recognized safety profiles at recommended dosages, potential interactions within unified formulations require evaluation. Comprehensive toxicological assessment, including evaluation of hepatic and renal function, should precede clinical application. Contraindications, including pregnancy, lactation, and specific disease states, must be clearly defined.

Clinical Trial Design: Rigorous evaluation requires randomized, double-blind, placebo-controlled trials with adequate sample sizes and duration to assess clinically relevant endpoints. Primary outcomes should include validated biomarkers of inflammation (high-sensitivity C-reactive protein, IL-6, TNF-α), oxidative stress (malondialdehyde, oxidized LDL, F_2-isoprostanes), lipid profiles, glycemic indices (fasting glucose, HbA1c, HOMA-IR), anthropometric measures, and cardiovascular function (endothelial function, arterial stiffness, blood pressure). Long-term studies examining cardiovascular event reduction would provide definitive evidence but require substantial resources.

Regulatory Considerations: Classification as dietary supplements versus therapeutic agents varies by jurisdiction and influences regulatory requirements. Claims regarding disease prevention or treatment require substantiation through clinical evidence meeting regulatory standards.

Sustainability and Accessibility: The global dietary supplement market growth reflects increasing health awareness and chronic disease burden. Development of evidence-based, standardized formulations with demonstrated efficacy could provide accessible, cost-effective adjunctive strategies for chronic disease management, particularly in populations with limited access to pharmaceutical interventions. Sustainable sourcing of botanical ingredients and environmentally responsible production practices should be prioritized.

---

7. LIMITATIONS

This hypothesis-driven analysis is subject to several important limitations that must be acknowledged:

Absence of Direct Evidence: The primary limitation is the lack of experimental data directly evaluating the proposed unified formulation. All mechanistic inferences are extrapolated from studies examining individual compounds in isolation. Potential synergistic, additive, or antagonistic interactions between components remain speculative and require empirical validation.

Heterogeneity of Source Studies: The evidence base for individual compounds varies substantially in quality, with studies ranging from in vitro experiments and animal models to human observational studies and randomized controlled trials. Extrapolation from preclinical models to human physiology is inherently uncertain. Many human studies are limited by small sample sizes, short durations, heterogeneous populations, and variable methodological rigor.

Bioavailability Uncertainty: Polyphenolic compounds exhibit highly variable bioavailability influenced by food matrix effects, gut microbiota composition, genetic polymorphisms in metabolizing enzymes, and inter-individual variability. Whether therapeutic tissue

concentrations can be achieved through oral supplementation of the proposed formulation remains unknown. Potential competition for absorption pathways between multiple compounds administered simultaneously has not been evaluated.

Dose-Response Relationships: Optimal dosages for individual components within a unified formulation have not been established. Dose-response relationships may be non-linear, and potential for adverse effects at high doses or with prolonged use cannot be excluded. The assumption that combining multiple compounds at standard individual dosages will produce beneficial effects without toxicity requires validation.

Mechanistic Complexity: The molecular mechanisms underlying observed effects of bioactive compounds are incompletely understood. Many compounds exhibit pleiotropic effects through multiple pathways, and the relative contribution of specific mechanisms to overall physiological outcomes remains unclear. The proposed integrated model simplifies complex biological systems and may not capture important regulatory feedback loops or compensatory mechanisms.

Population Specificity: The potential efficacy of the proposed formulation may vary substantially across populations based on baseline nutritional status, genetic background, gut microbiota composition, disease state, concomitant medications, and lifestyle factors. Generalizability of findings from specific populations to broader groups is uncertain.

Publication Bias: The literature on bioactive compounds may be subject to publication bias, with positive findings more likely to be published than null or negative results. This may lead to overestimation of potential benefits.

Lack of Long-Term Safety Data: While individual components have established safety profiles at recommended dosages, long-term safety of unified formulations has not been evaluated. Potential for cumulative toxicity, nutrient imbalances, or unanticipated interactions with chronic use requires investigation.

Regulatory and Standardization Issues: Variability in botanical extract composition due to differences in plant cultivars, growing conditions, harvesting methods, and extraction procedures may result in inconsistent bioactive compound content. Lack of standardization complicates interpretation of existing literature and poses challenges for clinical application.

These limitations underscore that the present analysis constitutes a hypothesis-generating framework rather than evidence-based clinical guidance. Translation to clinical practice requires systematic experimental validation through appropriately designed studies addressing these limitations.

---

8. CONCLUSION

This hypothesis-driven mechanistic analysis synthesizes existing evidence regarding individual bioactive compounds—flavonoids, *Chlorella vulgaris*, green tea catechins, *Citrus sinensis* anthocyanins, spirulina, psyllium fiber, and fenugreek—to propose a theoretical framework for unified supplementation targeting inflammation, oxidative stress, and cardiovascular risk. The mechanistic plausibility of synergistic or additive effects is supported by complementary molecular pathways, including direct free radical scavenging, upregulation of endogenous antioxidant defenses, inhibition of pro-inflammatory signaling cascades, modulation of lipid metabolism and adipocytokine expression, and enhancement of insulin sensitivity.

The integrated physiological model presented suggests that simultaneous targeting of multiple interconnected pathophysiological pathways through a unified bioactive compound formulation may theoretically achieve more comprehensive metabolic and cardiovascular benefits than individual compounds administered in isolation. However, this hypothesis remains speculative and requires rigorous experimental validation.

Critical knowledge gaps include absence of direct evidence for combined formulations, uncertainty regarding bioavailability and potential interactions, lack of dose-response data for unified supplementation, and limited understanding of population-specific responses. Future research priorities include: (1) preclinical studies evaluating safety, bioavailability, and pharmacokinetic interactions of combined formulations; (2) mechanistic studies elucidating molecular pathways and potential synergistic effects; (3) randomized controlled trials examining effects on validated biomarkers of inflammation, oxidative stress, and cardiovascular risk in well-defined populations; and (4) long-term studies assessing clinical outcomes and safety profiles.

The growing global burden of cardiovascular disease and metabolic syndrome, coupled with limitations of current pharmacological approaches, justifies exploration of evidence-based nutritional strategies as adjunctive therapeutic modalities. The theoretical framework presented provides a foundation for systematic investigation of unified bioactive compound supplementation, with the ultimate goal of developing safe, effective, and accessible interventions for chronic disease prevention and management. However, translation from mechanistic plausibility to clinical application requires adherence to rigorous scientific standards and comprehensive evaluation of efficacy, safety, and cost-effectiveness through appropriately designed clinical trials.

9. CONFLICT OF INTEREST

The author declares no conflicts of interest related to this work. The study was conducted independently without external funding or commercial influence.

10. DATA AVAILABILITY STATEMENT

No new datasets were generated or analyzed during this study. All data supporting this work are derived from publicly available sources cited in the references.

REFERENCES

[1] Maughan RJ, Burke LM, Dvorak J, et al. IOC consensus statement: dietary supplements and the high-performance athlete. *Br J Sports Med*. 2018;52(7):439-455.

[2] U.S. Food and Drug Administration. Dietary Supplement Health and Education Act of 1994. Public Law 103-417. 1994.

[3] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Front Pharmacol*. 2014;4:177.

[4] Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation. *J Gen Intern Med*. 2008;23(6):854-859.

[5] Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. *J Am Coll Cardiol*. 2020;76(25):2982-3021.

[6] Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: impact on human health. *Pharmacogn Rev*. 2010;4(8):118-126.

[7] National Institutes of Health. Oxidative stress. National Cancer Institute Dictionary of Cancer Terms. Accessed 2023.

[8] Incalza MA, D'Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. *Vascul Pharmacol*. 2018;100:1-19.

[9] Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. *J Am Coll Cardiol*. 2003;42(7):1149-1160.

[10] Saklayen MG. The global epidemic of the metabolic syndrome. *Curr Hypertens Rep*. 2018;20(2):12.

[11] Medzhitov R. Origin and physiological roles of inflammation. *Nature*. 2008;454(7203):428-435.

[12] Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. *Nat Med*. 2019;25(12):1822-1832.

[13] Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. *Arch Med Sci*. 2017;13(4):851-863.

[14] Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. *Nutr Rev*. 2007;65(12 Pt 2):S140-S146.

[15] Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative stress and inflammation: what polyphenols can do for us? *Oxid Med Cell Longev*. 2016;2016:7432797.

[16] Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. *J Nutr Sci*. 2016;5:e47.

[17] Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. *Am J Clin Nutr*. 2008;88(1):38-50.

[18] Cassidy A, Rimm EB, O'Reilly EJ, et al. Dietary flavonoids and risk of stroke in women. *Stroke*. 2012;43(4):946-951.

[19] Somerville V, Bringans C, Braakhuis A. Polyphenols and performance: a systematic review and meta-analysis. *Sports Med*. 2017;47(8):1589-1599.

[20] Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. *J Agric Food Chem*. 2005;53(10):4290-4302.

[21] Huang D, Ou B, Prior RL. The chemistry behind antioxidant capacity assays. *J Agric Food Chem*. 2005;53(6):1841-1856.

[22] Kasote DM, Katyare SS, Hegde MV, Bae H. Significance of antioxidant potential of plants and its relevance to therapeutic applications. *Int J Biol Sci*. 2015;11(8):982-991.

[24] Safi C, Zebib B, Merah O, Pontalier PY, Vaca-Garcia C. Morphology, composition, production, processing and applications of *Chlorella vulgaris*: a review. *Renew Sustain Energy Rev*. 2014;35:265-278.

[25] Azocar J, Diaz A. Efficacy and safety of *Chlorella* supplementation in adults with chronic hepatitis C virus infection. *World J Gastroenterol*. 2013;19(7):1085-1090.

[26] Shim JY, Shin HS, Han JG, et al. Protective effects of *Chlorella vulgaris* on liver toxicity in cadmium-administered rats. *J Med Food*. 2008;11(3):479-485.

[27] Vijayavel K, Anbuselvam C, Balasubramanian MP. Antioxidant effect of *Chlorella vulgaris* against mercuric chloride induced nephrotoxicity in male albino rats. *Toxicol Mech Methods*. 2007;17(8):433-440.

[28] Aizzat O, Yap SW, Sopiah H, et al. Modulation of oxidative stress by *Chlorella vulgaris* in streptozotocin (STZ) induced diabetic Sprague-Dawley rats. *Adv Med Sci*. 2010;55(2):281-288.

[29] Hsu YW, Tsai CF, Chen WK, Huang CF, Yen CC. A subacute toxicity evaluation of green microalgae *Chlorella vulgaris* in BALB/cA mice. *Regul Toxicol Pharmacol*. 2008;52(1):24-30.

[30] Panahi Y, Ghamarchehreh ME, Beiraghdar F, Zare R, Jalalian HR, Sahebkar A. Investigation of the effects of *Chlorella vulgaris* supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. *Hepatogastroenterology*. 2012;59(119):2099-2103.

[31] Chaudhari SN, Mulay PA, Sahu NP, Pal AK. Effect of *Chlorella vulgaris* supplementation on health and growth of rohu (*Labeo rohita*) fingerlings. *Indian J Fish*. 2012;59(3):81-87.

[32] Kwak JH, Baek SH, Woo Y, et al. Beneficial immunostimulatory effect of short-term *Chlorella* supplementation: enhancement of natural killer cell activity and early inflammatory response (randomized, double-blinded, placebo-controlled trial). *Nutr J*. 2012;11:53.

[33] Bito T, Okumura E, Fujishima M, Watanabe F. Potential of *Chlorella* as a dietary supplement to promote human health. *Nutrients*. 2020;12(9):2524.

[34] Wu CH, Lu FH, Chang CS, Chang TC, Wang RH, Chang CJ. Relationship among habitual tea consumption, percent body fat, and body fat distribution. *Obes Res*. 2003;11(9):1088-1095.

[35] Hughes LA, Arts IC, Ambergen T, et al. Higher dietary flavone, flavonol, and catechin intakes are associated with less of an increase in BMI over time in women: a longitudinal analysis from the Netherlands Cohort Study. *Am J Clin Nutr*. 2008;88(5):1341-1352.

[36] Hursel R, Viechtbauer W, Westerterp-Plantenga MS. The effects of green tea on weight loss and weight maintenance: a meta-analysis. *Int J Obes (Lond)*. 2009;33(9):956-961.

[37] Phung OJ, Baker WL, Matthews LJ, Lanosa M, Thorne A, Coleman CI. Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis. *Am J Clin Nutr*. 2010;91(1):73-81.

[38] Jurgens TM, Whelan AM, Killian L, Doucette S, Kirk S, Foy E. Green tea for weight loss and weight maintenance in overweight or obese adults. *Cochrane Database Syst Rev*. 2012;12:CD008650.

[39] Khan N, Mukhtar H. Tea polyphenols in promotion of human health. *Nutrients*. 2018;11(1):39.

[40] Grosso G, Galvano F, Mistretta A, et al. Red orange: experimental models and epidemiological evidence of its benefits on human health. *Oxid Med Cell Longev*. 2013;2013:157240.

[41] Cardile V, Graziano AC, Venditti A. Clinical evaluation of *Moro* (*Citrus sinensis* (L.) Osbeck) orange juice supplementation for the weight management. *Nat Prod Res*. 2015;29(23):2256-2260.

[42] Saper RB, Eisenberg DM, Phillips RS. Common dietary supplements for weight loss. *Am Fam Physician*. 2004;70(9):1731-1738.

[43] Stohs SJ, Preuss HG, Shara M. A review of the human clinical studies involving *Citrus aurantium* (bitter orange) extract and its primary protoalkaloid p-synephrine. *Int J Med Sci*. 2012;9(7):527-538.

[44] Assini JM, Mulvihill EE, Huff MW. *Citrus* flavonoids and lipid metabolism. *Curr Opin Lipidol*. 2013;24(1):34-40.

[45] Mulvihill EE, Huff MW. Antiatherogenic properties of flavonoids: implications for cardiovascular health. *Can J Cardiol*. 2010;26(Suppl A):17A-21A.

[46] Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. *Adv Nutr*. 2014;5(4):404-417.

[47] Tsuda T. Dietary anthocyanin-rich plants: biochemical basis and recent progress in health benefits studies. *Mol Nutr Food Res*. 2012;56(1):159-170.

[48] Guo H, Xia M, Zou T, Ling W, Zhong R, Zhang W. Cyanidin 3-glucoside attenuates obesity-associated insulin resistance and hepatic steatosis in high-fat diet-fed and db/db mice via the transcription factor FoxO1. *J Nutr Biochem*. 2012;23(4):349-360.

[49] Habib MAB, Parvin M, Huntington TC, Hasan MR. A review on culture, production and use of spirulina as food for humans and feeds for domestic animals and fish. *FAO Fisheries and Aquaculture Circular*. 2008;No. 1034.

[50] Ciferri O. Spirulina, the edible microorganism. *Microbiol Rev*. 1983;47(4):551-578.

[51] Wu Q, Liu L, Miron A, Klímová B, Wan D, Kuča K. The antioxidant, immunomodulatory, and anti-inflammatory activities of spirulina: an overview. *Arch Toxicol*. 2016;90(8):1817-1840.

[52] Deng R, Chow TJ. Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae spirulina. *Cardiovasc Ther*. 2010;28(4):e33-e45.

[53] Calella P, Cerullo G, Di Dio M, et al. Antioxidant, anti-inflammatory and immunomodulatory effects of spirulina in exercise and sport: a systematic review. *Front Nutr*. 2022;9:1048258.

[57] Howarth NC, Saltzman E, Roberts SB. Dietary fiber and weight regulation. *Nutr Rev*. 2001;59(5):129-139.

[58] GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1923-1994.

[59] Ward NC, Watts GF, Eckel RH. Statin toxicity. *Circ Res*. 2019;124(2):328-350.

[60] Wei ZH, Wang H, Chen XY, et al. Time- and dose-dependent effect of psyllium on serum lipids in mild-to-moderate hypercholesterolemia: a meta-analysis of controlled clinical trials. *Eur J Clin Nutr*. 2009;63(7):821-827.

[61] Anderson JW, Allgood LD, Lawrence A, et al. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. *Am J Clin Nutr*. 2000;71(2):472-479.

[62] Slavin JL. Dietary fiber and body weight. *Nutrition*. 2005;21(3):411-418.

[63] Pal S, Radavelli-Bagatini S. Effects of psyllium on metabolic syndrome risk factors. *Obes Rev*. 2012;13(11):1034-1047.

[65] Wani SA, Kumar P. Fenugreek: a review on its nutraceutical properties and utilization in various food products. *J Saudi Soc Agric Sci*. 2018;17(2):97-106.

[66] Neelakantan N, Narayanan M, de Souza RJ, van Dam RM. Effect of fenugreek (*Trigonella foenum-graecum* L.) intake on glycemia: a meta-analysis of clinical trials. *Nutr J*. 2014;13:7.

[67] Basch E, Ulbricht C, Kuo G, Szapary P, Smith M. Therapeutic applications of fenugreek. *Altern Med Rev*. 2003;8(1):20-27.

[68] Kaviarasan S, Naik GH, Gangabhagirathi R, Anuradha CV, Priyadarsini KI. In vitro studies on antiradical and antioxidant activities of fenugreek (*Trigonella foenum graecum*) seeds. *Food Chem*. 2007;103(1):31-37.

[69] Sindhu G, Ratheesh M, Shyni GL, Nambisan B, Helen A. Anti-inflammatory and antioxidative effects of mucilage of *Trigonella foenum graecum* (Fenugreek) on adjuvant induced arthritic rats. *Int Immunopharmacol*. 2012;12(1):205-211.

[70] Bin-Hafeez B, Haque R, Parvez S, Pandey S, Sayeed I, Raisuddin S. Immunomodulatory effects of fenugreek (*Trigonella foenum graecum* L.) extract in mice. *Int Immunopharmacol*. 2003;3(2):257-265.

[71] Hannan JM, Ali L, Rokeya B, et al. Soluble dietary fibre fraction of *Trigonella foenum-graecum* (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. *Br J Nutr*. 2007;97(3):514-521.

[72] Grand View Research. Nutritional supplements market size, share & trends analysis report by ingredient, by form, by application, by end user, by distribution channel, by region, and segment forecasts, 2023-2030. Published 2023.

This preprint was submitted under the following conditions:

- The authors declare that the necessary Terms of Free and Informed Consent of participants or patients in the research were obtained and are described in the manuscript, when applicable.
- The authors declare that the preparation of the manuscript followed the ethical norms of scientific communication.
- The authors declare that they are aware that they are solely responsible for the content of the preprint and that the deposit in SciELO Preprints does not mean any commitment on the part of SciELO, except its preservation and dissemination.
- The authors declare that the data, applications, and other content underlying the manuscript are referenced.
- The deposited manuscript is in PDF format.
- The authors declare that the research that originated the manuscript followed good ethical practices and that the necessary approvals from research ethics committees, when applicable, are described in the manuscript.
- The authors declare that once a manuscript is posted on the SciELO Preprints server, it can only be taken down on request to the SciELO Preprints server Editorial Secretariat, who will post a retraction notice in its place.
- The authors agree that the approved manuscript will be made available under a Creative Commons CC-BY license.
- The submitting author declares that the contributions of all authors and conflict of interest statement are included explicitly and in specific sections of the manuscript.
- The authors declare that the manuscript was not deposited and/or previously made available on another preprint server or published by a journal.
- If the manuscript is being reviewed or being prepared for publishing but not yet published by a journal, the authors declare that they have received authorization from the journal to make this deposit.
- The submitting author declares that all authors of the manuscript agree with the submission to SciELO Preprints.